A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Latest Information Update: 31 Mar 2026
At a glance
- Drugs Insulin efsitora alfa (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
Most Recent Events
- 24 Mar 2026 Actual Primary Completion Date is 2 Jan 2026.
- 24 Mar 2026 Status changed from recruiting to completed.
- 03 Dec 2024 Planned primary completion date changed from 1 Nov 2025 to 1 Nov 2026.